Regeneron Pharmaceuticals REGN Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's deferred tax assets?
- Regeneron Pharmaceuticals (REGN) reported deferred tax assets of $4.19B in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred tax assets changed year-over-year?
- Regeneron Pharmaceuticals's deferred tax assets increased by 21.7% year-over-year, from $3.44B to $4.19B.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred tax assets has grown at a 36.5% compound annual growth rate (CAGR), from $858.9M to $4.08B.
- What does deferred tax assets mean?
- The value of future tax savings resulting from accounting differences or past losses.
- How do you interpret deferred tax assets?
- An increase may indicate the accumulation of tax credits or losses that can be used to offset future tax liabilities.
- How does deferred tax assets compare across companies?
- Common in capital-intensive and R&D-heavy industries where tax planning is a significant component of financial strategy.